The strategy was successfully applied to the preparation of a 99mTc-labeled conjugate comprising a tumor-targeting peptide sequence ([Cha13, Nle14]bombesin(7–14)) and a low molecular weight albumin binder, a pharmacological modifier to elongate the blood circulation time of the conjugate. The gene discussed is GRP; the disease is neoplasm.